triazoles has been researched along with hydroxyurea in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (28.57) | 18.7374 |
| 1990's | 3 (21.43) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Romagna, F; Suter, W | 1 |
| Hurlbert, RB; Moore, EC | 1 |
| Lewis, WH; Wright, JA | 1 |
| Adamson, RH; Hahn, MA | 1 |
| Bacon, PE; Cory, JG; Sato, A | 1 |
| Bailie, MB; Fink, GD; Pearson, JM; Roth, RA | 2 |
| Okpala, I | 1 |
| Hampton, T | 1 |
| Biruš, M; Butula, I; Dabelić, S; Jadrijević-Mladar, M; Kos, I; Maravić-Vlahoviček, G | 1 |
| Alvarez, O; Aygun, B; Bonner, M; Flanagan, J; Lockhart, A; Miller, ST; Mueller, BU; Owen, W; Schultz, W; Scott, JP; Ware, RE; Yovetich, NA | 1 |
| Barrette, S; Files, B; Habr, D; Minniti, CP; Torres, M; Vichinsky, E; Zhang, Y | 1 |
| Huang, X; Jiang, B; Jiang, J; Jiang, S; Lu, T; Wang, Q; Wu, X; Xu, J; Yao, H | 1 |
| Cohen, AR; Davis, BR; Heeney, MM; Kwiatkowski, JL; Lee, MT; Odame, I; Owen, WC; Pressel, S; Rogers, ZR; Schultz, WH; St Pierre, T; Ware, RE; Wood, JC | 1 |
2 review(s) available for triazoles and hydroxyurea
| Article | Year |
|---|---|
The inhibition of ribonucleoside diphosphate reductase by hydroxyurea, guanazole and pyrazoloimidazole (IMPY).
Topics: Abnormalities, Drug-Induced; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Survival; Cells, Cultured; DNA; DNA Repair; DNA Replication; Drug Resistance; Guanazole; Histones; Humans; Hydroxyurea; In Vitro Techniques; Mutagens; Pyrazoles; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; Structure-Activity Relationship; Triazoles | 1985 |
Investigational agents for sickle cell disease.
Topics: Acetamides; Anemia, Sickle Cell; Animals; Antihypertensive Agents; Antisickling Agents; Benzaldehydes; Benzoates; Carnitine; Cell Adhesion; Deferasirox; Endothelium, Vascular; Etilefrine; Female; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Hypertension, Pulmonary; Iron Chelating Agents; Male; Membrane Glycoproteins; Potassium Channels, Calcium-Activated; Priapism; Recombinant Fusion Proteins; Triazoles; Trityl Compounds; Vasoconstrictor Agents | 2006 |
3 trial(s) available for triazoles and hydroxyurea
| Article | Year |
|---|---|
Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.
Topics: Acute Chest Syndrome; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Benzoates; Chelation Therapy; Child; Child, Preschool; Cohort Studies; Deferasirox; Female; Humans; Hydroxyurea; Incidence; Iron Chelating Agents; Iron Overload; Male; Pain Measurement; Phlebotomy; Secondary Prevention; Stroke; Transfusion Reaction; Triazoles; Young Adult | 2013 |
Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
Topics: Acute Kidney Injury; Adolescent; Adult; Anemia, Sickle Cell; Benzoates; Cellulitis; Chelation Therapy; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Deferasirox; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Hydroxyurea; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Prospective Studies; Transfusion Reaction; Triazoles; Young Adult | 2013 |
Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Benzoates; Biological Assay; Child; Child, Preschool; Deferasirox; Deferoxamine; Female; Humans; Hydroxyurea; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Stroke; Transfusion Reaction; Triazoles; Ultrasonography, Doppler, Transcranial | 2015 |
9 other study(ies) available for triazoles and hydroxyurea
| Article | Year |
|---|---|
DNA repair induced by various mutagens in rat hepatocyte primary cultures measured in the presence of hydroxyurea, guanazole or aphidicolin.
Topics: Animals; Aphidicolin; Cells, Cultured; Diterpenes; DNA Damage; DNA Repair; Guanazole; Hydroxyurea; Liver; Male; Mutagenicity Tests; Mutagens; Rats; Rats, Inbred Strains; Salmonella typhimurium; Triazoles; Ultraviolet Rays | 1990 |
Altered ribonucleotide reductase activity in mammalian tissue culture cells resistant to hydroxyurea.
Topics: Animals; Binding Sites; Cell Line; Cells, Cultured; Cricetinae; Culture Media; Diamines; Dose-Response Relationship, Drug; Drug Resistance; Female; Genes; Hydroxyurea; L Cells; Mice; Ovary; Ribonucleotide Reductases; Thymidine; Time Factors; Triazoles; Tritium | 1974 |
Pharmacology of 3,5-diamino-1,24-triazole (guanazole). 1. Antitumor activity of guanazole.
Topics: Amines; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Cyclophosphamide; Cytarabine; Depression, Chemical; Female; Hydroxyurea; In Vitro Techniques; Leukemia L1210; Leukemia, Experimental; Lymphoma, Large B-Cell, Diffuse; Male; Mast-Cell Sarcoma; Methotrexate; Mice; Neoplasms, Experimental; Nitrosourea Compounds; Plasmacytoma; Structure-Activity Relationship; Triazoles | 1972 |
Studies on the differential mechanisms of inhibition of ribonucleotide reductase by specific inhibitors of the non-heme iron subunit.
Topics: Anaerobiosis; Animals; Catalase; Cell Division; Cells, Cultured; Deferoxamine; Guanazole; Humans; Hydroxyurea; Isoenzymes; Isoquinolines; Leukemia L1210; Peroxidase; Peroxidases; Pyrazoles; Quinolines; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; Triazoles | 1984 |
Platelet activating factor receptor blockade alone or in combination with leukotriene synthesis inhibition does not ameliorate alpha-naphthylisothiocyanate-induced hepatotoxicity.
Topics: 1-Naphthylisothiocyanate; Animals; Azepines; Hydroxyurea; Leukotrienes; Lipoxygenase Inhibitors; Liver; Male; Platelet Activating Factor; Rats; Rats, Sprague-Dawley; Triazoles | 1996 |
Neither platelet activating factor nor leukotrienes are critical mediators of liver injury after lipopolysaccharide administration.
Topics: Administration, Oral; Alanine Transaminase; Animals; Azepines; Blood Platelets; Chemical and Drug Induced Liver Injury; Female; Fibrinogen; Hydroxyurea; Injections, Intraperitoneal; Injections, Intravenous; Leukotrienes; Lipopolysaccharides; Lipoxygenase Inhibitors; Liver; Liver Diseases; Necrosis; Neutrophils; Platelet Activating Factor; Platelet Aggregation Inhibitors; Rats; Rats, Sprague-Dawley; Thrombocytopenia; Triazoles | 1997 |
Strides made in red blood cell disorders, but substantial barriers to care remain.
Topics: Anemia, Sickle Cell; Antisickling Agents; Benzoates; Brain Diseases; Chelation Therapy; Deferasirox; Hematologic Diseases; Hematology; Humans; Hydroxyurea; Iron Chelating Agents; Triazoles | 2008 |
Synthesis, antibacterial and cytotoxic activity evaluation of hydroxyurea derivatives.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Biuret; Escherichia coli; Humans; Hydroxyurea; Isomerism; Jurkat Cells; Microbial Sensitivity Tests; Structure-Activity Relationship; Triazines; Triazoles | 2013 |
Discovery of potential anti-inflammatory drugs: diaryl-1,2,4-triazoles bearing N-hydroxyurea moiety as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 5-Lipoxygenase; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Discovery; Hydroxyurea; Lipoxygenase Inhibitors; Structure-Activity Relationship; Triazoles | 2014 |